BACKGROUND: The increasing incidence of oropharyngeal cancer in many developed countries has been attributed to human papillomavirus type 16 (HPV16) infections. Recently, HPV16 E6 serology has been identified as a promising early marker for oropharyngeal cancer. Therefore, characterization of HPV16 E6 seropositivity among individuals without cancer is warranted. METHODS: A total of 4,666 controls were pooled from several studies of cancer and HPV seropositivity, all tested within the same laboratory. HPV16 E6 seropositive controls were classified as having (i) moderate [mean fluorescent intensity (MFI) ≥ 484 and <1,000] or (ii) high seroreactivity (MFI ≥ 1,000). Associations of moderate and high HPV16 E6 seroreactivity with (i) demographic risk factors; and seropositivity for (ii) other HPV16 proteins (E1, E2, E4, E7, and L1), and (iii) E6 proteins from non-HPV16 types (HPV6, 11, 18, 31, 33, 45, and 52) were evaluated. RESULTS: Thirty-two (0.7%) HPV16 E6 seropositive controls were identified; 17 (0.4%) with moderate and 15 (0.3%) with high seroreactivity. High HPV16 E6 seroreactivity was associated with former smoking [odds ratio (OR), 5.5; 95% confidence interval (CI), 1.2-51.8], and seropositivity against HPV16 L1 (OR, 4.8; 95% CI, 1.3-15.4); E2 (OR, 7.7; 95% CI, 1.4-29.1); multiple HPV16 proteins (OR, 25.3; 95% CI, 2.6-119.6 for three HPV16 proteins beside E6) and HPV33 E6 (OR, 17.7; 95% CI, 1.9-81.8). No associations were observed with moderate HPV16 E6 seroreactivity. CONCLUSIONS: High HPV16 E6 seroreactivity is rare among individuals without diagnosed cancer and was not explained by demographic factors. IMPACT: Some HPV16 E6 seropositive individuals without diagnosed HPV-driven cancer, especially those with seropositivity against other HPV16 proteins, may harbor a biologically relevant HPV16 infection.

Cancer Epidemiology Unit Nuffield Department of Population Health University of Oxford Oxford United Kingdom

Centre for Research in Epidemiology and Population Health Villejuif France Université Paris Sud Villejuif France Institut Gustave Roussy Villejuif France

Charles University Prague 1st Faculty of Medicine Prague Czech Republic

CRO Aviano National Cancer Institute Aviano Italy

Croatian National Institute of Public Health Zagreb Croatia

Danish Cancer Society Research Center Copenhagen Denmark

Department of Clinical Sciences Lund University Lund Sweden

Department of Medical Sciences University of Turin Turin Italy

Department of Research Cancer Registry of Norway Oslo Norway

Department of Research Cancer Registry of Norway Oslo Norway Department of Community Medicine Faculty of Health Sciences University of Tromsø The Arctic University of Norway Tromsø Norway Department of Medical Epidemiology and Biostatistics Karolinska Institutet Stockholm Sweden Genetic Epidemiology Group Folkhälsan Research Center Helsinki Finland

Escuela Andaluza de Salud Pública Instituto de Investigación Biosanitaria ibs GRANADA Hospitales Universitarios de Granada Universidad de Granada Granada Spain CIBER de Epidemiología y Salud Pública Madrid Spain

Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

German Cancer Research Center Heidelberg Germany

Hellenic Health Foundation Athens Greece Academy of Athens Athens Greece University of Athens Medical School Athens Greece

Imperial College London London United Kingdom

International Agency for Research on Cancer Lyon France

Laboratory of Public Health and Population Studies Department of Molecular Medicine University of Padova Padova Italy

Leibniz Institute for Prevention Research and Epidemiology Bremen Germany

National Cancer Institute NIH Bethesda Maryland

National Cancer Institute NIH Bethesda Maryland Ontario Institute for Cancer Research Toronto Ontario Canada

National Institute for Public Health and the Environment Bilthoven the Netherlands University Medical Centre Utrecht the Netherlands The School of Public Health Imperial College London London United Kingdom University of Malaya Kuala Lumpur Malaysia

Trinity College School of Dental Science Dublin Ireland

Unit of Infections and Cancer Institut Català d'Oncologia IDIBELL CIBERESP L'Hospitalet de Llobregat Catalonia Spain

University of Aberdeen Aberdeen United Kingdom

University of Athens Medical School Athens Greece

University of Glasgow Glasgow United Kingdom University of Aberdeen Aberdeen United Kingdom

University of Newcastle on Tyne Newcastle United Kingdom

000      

00000naa a2200000 a 4500

001      

bmc16010607

003      

CZ-PrNML

005      

20160412120801.0

007      

ta

008      

160408s2015 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1158/1055-9965.EPI-14-1217 $2 doi

024    7_

$a 10.1158/1055-9965.EPI-14-1217 $2 doi

035    __

$a (PubMed)25623733

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Lang Kuhs, Krystle A $u National Cancer Institute, NIH, Bethesda, Maryland. Krystle.Kuhs@nih.gov.

245    10

$a Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled Analysis / $c KA. Lang Kuhs, D. Anantharaman, T. Waterboer, M. Johansson, P. Brennan, A. Michel, M. Willhauck-Fleckenstein, MP. Purdue, I. Holcátová, W. Ahrens, P. Lagiou, J. Polesel, L. Simonato, F. Merletti, CM. Healy, K. Kjaerheim, DI. Conway, TV. Macfarlane, P. Thomson, X. Castellsagué, A. Znaor, A. Black, WY. Huang, V. Krogh, A. Trichopoulou, HB. Bueno-de-Mesquita, F. Clavel-Chapelon, E. Weiderpass, J. Ekström, E. Riboli, A. Tjønneland, MJ. Sánchez, RC. Travis, A. Hildesheim, M. Pawlita, AR. Kreimer,

520    9_

$a BACKGROUND: The increasing incidence of oropharyngeal cancer in many developed countries has been attributed to human papillomavirus type 16 (HPV16) infections. Recently, HPV16 E6 serology has been identified as a promising early marker for oropharyngeal cancer. Therefore, characterization of HPV16 E6 seropositivity among individuals without cancer is warranted. METHODS: A total of 4,666 controls were pooled from several studies of cancer and HPV seropositivity, all tested within the same laboratory. HPV16 E6 seropositive controls were classified as having (i) moderate [mean fluorescent intensity (MFI) ≥ 484 and <1,000] or (ii) high seroreactivity (MFI ≥ 1,000). Associations of moderate and high HPV16 E6 seroreactivity with (i) demographic risk factors; and seropositivity for (ii) other HPV16 proteins (E1, E2, E4, E7, and L1), and (iii) E6 proteins from non-HPV16 types (HPV6, 11, 18, 31, 33, 45, and 52) were evaluated. RESULTS: Thirty-two (0.7%) HPV16 E6 seropositive controls were identified; 17 (0.4%) with moderate and 15 (0.3%) with high seroreactivity. High HPV16 E6 seroreactivity was associated with former smoking [odds ratio (OR), 5.5; 95% confidence interval (CI), 1.2-51.8], and seropositivity against HPV16 L1 (OR, 4.8; 95% CI, 1.3-15.4); E2 (OR, 7.7; 95% CI, 1.4-29.1); multiple HPV16 proteins (OR, 25.3; 95% CI, 2.6-119.6 for three HPV16 proteins beside E6) and HPV33 E6 (OR, 17.7; 95% CI, 1.9-81.8). No associations were observed with moderate HPV16 E6 seroreactivity. CONCLUSIONS: High HPV16 E6 seroreactivity is rare among individuals without diagnosed cancer and was not explained by demographic factors. IMPACT: Some HPV16 E6 seropositive individuals without diagnosed HPV-driven cancer, especially those with seropositivity against other HPV16 proteins, may harbor a biologically relevant HPV16 infection.

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    _2

$a protilátky virové $x krev $7 D000914

650    _2

$a spinocelulární karcinom $x imunologie $x virologie $7 D002294

650    _2

$a studie případů a kontrol $7 D016022

650    _2

$a kohortové studie $7 D015331

650    _2

$a ELISA $7 D004797

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidský papilomavirus 16 $x imunologie $7 D052162

650    _2

$a lidé $7 D006801

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a onkogenní proteiny virové $x imunologie $7 D009856

650    _2

$a nádory orofaryngu $x imunologie $x virologie $7 D009959

650    _2

$a infekce papilomavirem $x imunologie $7 D030361

650    _2

$a represorové proteiny $x imunologie $7 D012097

650    _2

$a rizikové faktory $7 D012307

650    _2

$a mladý dospělý $7 D055815

655    _2

$a časopisecké články $7 D016428

655    _2

$a Research Support, N.I.H., Intramural $7 D052060

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Anantharaman, Devasena $u International Agency for Research on Cancer (IARC), Lyon, France. $7 gn_A_00005858

700    1_

$a Waterboer, Tim $u German Cancer Research Center (DKFZ), Heidelberg, Germany.

700    1_

$a Johansson, Mattias $u International Agency for Research on Cancer (IARC), Lyon, France.

700    1_

$a Brennan, Paul $u International Agency for Research on Cancer (IARC), Lyon, France.

700    1_

$a Michel, Angelika $u German Cancer Research Center (DKFZ), Heidelberg, Germany.

700    1_

$a Willhauck-Fleckenstein, Martina $u German Cancer Research Center (DKFZ), Heidelberg, Germany.

700    1_

$a Purdue, Mark P $u National Cancer Institute, NIH, Bethesda, Maryland. Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

700    1_

$a Holcátová, Ivana $u Charles University in Prague, 1st Faculty of Medicine, Prague, Czech Republic.

700    1_

$a Ahrens, Wolfgang $u Leibniz Institute for Prevention Research and Epidemiology, Bremen, Germany. $7 gn_A_00002543

700    1_

$a Lagiou, Pagona $u University of Athens Medical School, Athens, Greece.

700    1_

$a Polesel, Jerry $u CRO Aviano National Cancer Institute, Aviano, Italy.

700    1_

$a Simonato, Lorenzo $u Laboratory of Public Health and Population Studies, Department of Molecular Medicine, University of Padova, Padova, Italy.

700    1_

$a Merletti, Franco $u Department of Medical Sciences, University of Turin, Turin, Italy.

700    1_

$a Healy, Claire M $u Trinity College School of Dental Science, Dublin, Ireland.

700    1_

$a Kjaerheim, Kristina $u Department of Research, Cancer Registry of Norway, Oslo, Norway.

700    1_

$a Conway, David I $u University of Glasgow, Glasgow, United Kingdom. University of Aberdeen, Aberdeen, United Kingdom.

700    1_

$a Macfarlane, Tatiana V $u University of Aberdeen, Aberdeen, United Kingdom.

700    1_

$a Thomson, Peter $u University of Newcastle on Tyne, Newcastle, United Kingdom.

700    1_

$a Castellsagué, Xavier $u Unit of Infections and Cancer, Institut Català d'Oncologia (ICO), IDIBELL, CIBERESP, L'Hospitalet de Llobregat, Catalonia, Spain.

700    1_

$a Znaor, Ariana $u Croatian National Institute of Public Health, Zagreb, Croatia.

700    1_

$a Black, Amanda $u National Cancer Institute, NIH, Bethesda, Maryland.

700    1_

$a Huang, Wen-Yi $u National Cancer Institute, NIH, Bethesda, Maryland.

700    1_

$a Krogh, Vittorio $u Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

700    1_

$a Trichopoulou, Antonia $u Hellenic Health Foundation, Athens, Greece. Academy of Athens, Athens, Greece. University of Athens Medical School, Athens, Greece.

700    1_

$a Bueno-de-Mesquita, H B As $u National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. University Medical Centre, Utrecht, the Netherlands. The School of Public Health, Imperial College London, London, United Kingdom. University of Malaya, Kuala Lumpur, Malaysia.

700    1_

$a Clavel-Chapelon, Françoise $u Centre for Research in Epidemiology and Population Health (CESP), Villejuif, France. Université Paris Sud, Villejuif, France. Institut Gustave Roussy, Villejuif, France.

700    1_

$a Weiderpass, Elisabete $u Department of Research, Cancer Registry of Norway, Oslo, Norway. Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland.

700    1_

$a Ekström, Johanna $u Department of Clinical Sciences, Lund University, Lund, Sweden.

700    1_

$a Riboli, Elio $u Imperial College London, London, United Kingdom.

700    1_

$a Tjønneland, Anne $u Danish Cancer Society Research Center, Copenhagen, Denmark.

700    1_

$a Sánchez, María-José $u Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

700    1_

$a Travis, Ruth C $u Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

700    1_

$a Hildesheim, Allan $u National Cancer Institute, NIH, Bethesda, Maryland.

700    1_

$a Pawlita, Michael $u German Cancer Research Center (DKFZ), Heidelberg, Germany.

700    1_

$a Kreimer, Aimée R $u National Cancer Institute, NIH, Bethesda, Maryland.

773    0_

$w MED00006442 $t Cancer epidemiology, biomarkers & prevention a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology $x 1538-7755 $g Roč. 24, č. 4 (2015), s. 683-9

856    41

$u https://pubmed.ncbi.nlm.nih.gov/25623733 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20160408 $b ABA008

991    __

$a 20160412120844 $b ABA008

999    __

$a ok $b bmc $g 1114036 $s 934975

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2015 $b 24 $c 4 $d 683-9 $e 20150126 $i 1538-7755 $m Cancer epidemiology, biomarkers & prevention $n Cancer Epidemiol Biomarkers Prev $x MED00006442

LZP    __

$a Pubmed-20160408